Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis
Nedaplatin showed fewer adverse effects and comparable or improved short-term outcomes compared with cisplatin. These findings support nedaplatin as a potential alternative for patients who are cisplatin-intolerant or frail. Confirmation in large, high-quality trials with long-term follow-up and patient-reported outcomes is warranted.
Authors
- Takahiro Itaya (ORCID: https://orcid.org/0000-0002-0560-8686)
- Yoshie Yamada (ORCID: https://orcid.org/0000-0002-0424-3750)
- Masaki Mandai (ORCID: https://orcid.org/0000-0003-4428-8029)
- Kazuhiro Kou
- Yoshihide Inayama (ORCID: https://orcid.org/0000-0003-2040-5913)
- K Yamaguchi
- Yosuke Yamamoto
- Maki Umemiya (ORCID: https://orcid.org/0000-0002-5097-3543)
- Jun Kamei
Institutions
- Hiroshima University (JP)
- Kyoto University (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1007/s10147-026-02968-6
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Asahi Kasei Pharma Corporation
- Nippon Shinyaku
- Ono Pharmaceutical
- Pfizer Japan
- MSD K.K.
- Eli Lilly Japan